COMPASS Pathways is progressing its lead investigational psilocybin-based treatment, COMP360, targeting treatment-resistant depression (TRD) with pivotal Phase 3 trial data underpinning an anticipated regulatory submission. The company continues to operate at a significant operating loss while preparing for potential commercial launch, investing heavily in clinical development, manufacturing scale-up, and regulatory compliance activities. Reliance on third-party contract manufacturers and regulatory uncertainties around controlled substances constitute material operating risks. Financially, COMPASS carries moderate debt alongside over $430 million in cash but faces increasing expenditure demands ahead of product approval.